SB 202190 , 99% , 152121-30-7
Synonym(s):
4-(4-Fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)-1H-imidazole;4-(4-Fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)1H-imidazole, FHPI, p38 MAP Kinase Inhibitor II;InSolution p38 MAP Kinase Inhibitor II;InSolution SB 202190 - CAS 152121-30-7 - Calbiochem;SB 202190 - CAS 152121-30-7 - Calbiochem
Pack Size | Price | Stock | Quantity |
5MG | RMB181.60 | In Stock |
|
25MG | RMB634.40 | In Stock |
|
100MG | RMB1412.80 | In Stock |
|
others | Enquire |
PRODUCT Properties
Melting point: | 240-243℃ |
Boiling point: | 565.7±50.0 °C(Predicted) |
Density | 1.31 |
RTECS | SL4584000 |
storage temp. | 2-8°C |
solubility | DMSO: 30 mg/mL, soluble |
pka | 9.14±0.15(Predicted) |
form | Pale yellow solid |
color | pale yellow |
Stability: | Stable for 2 years from date of purchase as supplied. Solutions in DMSO may be stored at -20° for up to 2 months. |
InChIKey | QHKYPYXTTXKZST-UHFFFAOYSA-N |
Description and Uses
SB 202190 is a selective, potent, cell-
SB 202190 is a DFG inhibitor used in the treatment of colorectal cancer. It is a highly selective, potent inhibitor of p38 MAP kinase. SB-202190 is able to promote proliferation of C6 cells in lower concentration but induced apoptosis in higher levels. Studies show that SB202190 can protect neural function from ischemia/reperfusion injury and regulate the activation of Bcl-2 and Bax protein after ischemia/reperfusion in rat.
Safety
Symbol(GHS) | GHS07 |
Signal word | Warning |
Hazard statements | H315-H319-H335 |
Precautionary statements | P261-P280a-P304+P340-P305+P351+P338-P405-P501a |
Hazard Codes | Xi |
Risk Statements | 36/37/38 |
Safety Statements | 26-36/37 |
WGK Germany | 3 |
HS Code | 29333990 |